Here is a refresher on the mechanism of action of leronlimab that turns cold tumors into hot ones, thereby making them eligible to be treated with a PD-1 inhibitor.

Tumor's PD-L1 Upregulation

Unmasking the Mechanism

Remember, this 2nd mechanism of action would best be utilized in combination with subsequent treatment by a PD-1 blocker.

Don't forget that leronlimab has its own Primary Stand Alone mechanism of action as well, which has nothing to do with the upregulation of PD-L1 on tumor's CTC cells.